Drug-labels.com

Eucrisa: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
2 %
Active ingredient:

Patient Medication Information: uses, side effects, how to take - Eucrisa

What is EUCRISA used for?

  • EUCRISA is used for adults and children (3 months of age and older) to treat mild to moderate eczema (atopic dermatitis).

How does EUCRISA work?

EUCRISA belongs to a group of medicines known as a “phosphodiesterase-4 (PDE-4) inhibitor”. It is a non-steroid prescription medicine and the exact way it works is not known. EUCRISA is thought that it reduces the amount of substances in the body that trigger the rash and itchiness caused by eczema.

What are the ingredients in EUCRISA?

Medicinal ingredient: Crisaborole.

Non-medicinal ingredients: Butylated hydroxytoluene, edetate calcium disodium, mono- and di-glycerides, paraffin, propylene glycol, and white petrolatum.

EUCRISA comes in the following dosage forms:

Ointment: 2% w/w (20 mg per gram) of crisaborole.

Do not use EUCRISA if:

  • you or your child are allergic to crisaborole or any of the other ingredients in EUCRISA.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take EUCRISA. Talk about any health conditions or problems you may have, including if you:

  • are pregnant or planning to become pregnant. It is not known if EUCRISA may harm your unborn baby.

  • are breast-feeding or planning to breast-feed. It is not known if EUCRISA passes into breast milk. Talk with your healthcare profesional about the best way to feed your baby if you take EUCRISA.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with EUCRISA:

  • There are no relevant interactions with EUCRISA at this time.

How to take EUCRISA:

  • Use EUCRISA exactly as directed by your healthcare professional.
  • EUCRISA is a topical medicine that is only to be applied onto the affected area(s) of the skin. Do NOT use in your eyes, mouth, or vagina.
  • Rinse with water if this medicine gets in you or your child’s eyes, mouth, or vagina.
  • Wash your hands after applying EUCRISA, unless you are using it to treat eczema on your hands. All caregivers who apply EUCRISA for someone else should wash their hands after applying it.

Usual dose:

Your healthcare professional will tell you how often to apply EUCRISA. This will be based on your or your child’s medical condition and response to the EUCRISA.

The usual dose is to apply a thin layer of EUCRISA to affected area(s) twice daily.

When your or your child’s eczema is clear or almost clear, your healthcare professional may reduce your dose to once daily to the most commonly affected area(s). However, if your or your child’s eczema worsens, your healthcare professional may increase your dose to twice daily to the affected area(s).

Overdose:

If you think that you or your child has applied too much EUCRISA, thoroughly wipe it off.

If you think you, or a person you are caring for, have taken too much EUCRISA, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you or your child miss or forget to use EUCRISA, apply it as soon as you remember. Then go back to the regular dosing schedule. Do NOT apply twice as much the next time you use it.

What are possible side effects from using EUCRISA?

These are not all the possible side effects you may have when taking EUCRISA. If you experience any side effects not listed here, tell your healthcare professional.

Serious side effects and what to do about them

Symptom / effectTalk to your healthcare professionalStop taking drug and get immediate medical help
Only if severeIn all cases
VERY COMMON
Application site reactions: burning, itching, inflamed skin, or stinging.X
RARE
Allergic reactions (at or near the application site): hives, itching, swelling, or redness.X

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

  • Visiting the Web page on Adverse Reaction Reporting (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html) for information on how to report online, by mail or by fax; or
  • Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store EUCRISA below 25°C.

Keep out of reach and sight of children.

If you want more information about EUCRISA:

  • Talk to your healthcare professional.
  • Find the full Product Monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website

    • (https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html); the manufacturer’s website (http://www.Pfizer.ca), or by calling 1-800-463-6001.

Last Revised: AUG 29, 2023

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02476991

Revision date stated in the text: August 29, 2023

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Eucrisa

Rx or OTC
Prescription (Rx)?
DIN 02476991
Schedule(s) PRESCRIPTION
Active ingredient(s) Crisaborole 2 %
Dosage form(s) Ointment
Route(s) of administration Topical
Drug class (WHO ATC)
  1. D Dermatologicals
    1. D11 Other dermatological preparations
      1. D11A Other dermatological preparations
        1. D11AH Agents for dermatitis, excluding corticosteroids
          1. D11AH06 Crisaborole
Company PFIZER CANADA ULC
Current status Marketed
Current status date August 29, 2018

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.